leisure time -WSS

leisure time

author：explore 2025-10-03 22:52:38 - browse：34432

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： What affirmative action's end means to a medical student

entertainment

WSS

A new ‘biological computer' targets cancer while sparing healthy cells

A new ‘biological computer' targets cancer while sparing healthy cells

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

How Robert F. Kennedy Jr. distorted vaccine science

What affirmative action's end means to a medical student

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

As demand for Covid shots wanes, Moderna seeks its next success

STAT wants to know your pick for a great summer read or listen

Activists slam private health insurers over coverage restrictions

What affirmative action's end means to a medical student

Virginia high school admissions case could be legal follow

Hormonal contraceptives don’t actually treat endometriosis

Psychedelics group wrestles with new pharma identity

Judge denies Trump's request for new trial in E. Jean Carroll case

Wikipedia

When a patient nears the end, a feared therapy can comfort

Hubble vs. James Webb telescope images: See the difference

Vertex cell therapy lets patients with type 1 diabetes stop insulin

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Undocumented workers face uncertainty as immigration law takes effect in Florida

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

focus

entertainment

hotspot

explore